AI-powered supportive care chatbot for young adult cancer survivors
Official title: Feasibility, Usability, and Acceptability of an AI-Powered MASCC Supportive Care Platform Among Young Adults With Cancer
Run by University of Michigan Rogel Cancer Center · NCT07772596 · Data updated 2026-11-12
A chatbot driven by artificial intelligence is tested to help young adult cancer survivors manage symptoms and care needs after treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 39 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | University of Michigan Rogel Cancer Center Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 1 site (Ann Arbor, Michigan) |
| Status | Recruiting |
| Started | September 15, 2026 |
| Main results expected | September 2028 |
| Study ends | September 2028 |
| Registry record updated | October 15, 2026 |
| Trial ID | NCT07772596 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Young adults aged 18-39 who have completed primary cancer treatment (within the last month or on maintenance therapy), report at least one moderate to severe symptom, and have internet access.
✕Probably not a fit
Participants not experiencing bothersome symptoms or unable to use an AI chatbot may derive little or no benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study examines whether an AI-supported chatbot can provide tailored information and guidance on symptom management, treatment effects, and transitions back to daily life for young adults (18-39) who completed cancer treatment. Participants interact with the chatbot through free-text questions or selected topics and receive evidence-based educational responses. The study focuses on addressing moderate to severe symptoms and support concerns, using surveys to gauge usefulness and impact. It is led by the University of Michigan Rogel Cancer Center and conducted at that site. Eligibility includes English-speaking individuals within the age range who have internet access and completed primary treatment within the past month (or are on maintenance therapy).
Why it matters
Potential benefit: If successful, participants may experience improved symptom management and clearer guidance for navigating post-treatment needs.
How similar studies have gone: Previous AI-based support tools in oncology have shown promise in symptom guidance and patient education, but this exact approach for young adult survivors is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 - 39 years old * Able to speak/read English * Completed primary cancer treatment (e.g., surgery, radiation, chemotherapy, immunotherapy) at least one month prior to the time of consent. Although, participants will be eligible if they are receiving maintenance treatments * Report at least one moderate to severe symptom, side effect, or supportive care concern from cancer or its treatment * Able to access Wi-Fi/internet * Willing to complete surveys electronically Exclusion Criteria: * Completed cancer treatment more than three years ago
Where it's running
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, United States Recruiting
Study contacts
- Principal investigator: Robert Knoerl — University of Michigan Rogel Cancer Center
- Study coordinator: Robert Knoerl
- Email: rjknoerl@med.umich.edu
- Phone: 734-764-8617
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
See if virtual informed consent methods help people decide to join cancer research
This trial tests whether virtual human communicators and different consent messages can influence cancer patients’ understanding and willingness to participate in research.
-
Telehealth pharmacist-led opioid education for cancer patients
This pilot tests a telehealth group education session led by a palliative care pharmacist to help adults with cancer use opioids more safely and effectively.
-
Mindfulness program to help with symptoms in chronic graft-versus-host disease
A mindfulness-based program is being tested to see if it can reduce patient-reported symptoms for adults with chronic graft-versus-host disease after a stem cell transplant.
-
Non-invasive brain stimulation to help chemotherapy-induced nerve problems in cancer survivors
This trial tests whether a gentle brain stimulation method (tDCS) can help reduce numbness, tingling, and pain from CIPN in cancer survivors who are not currently in treatment.
-
Ambient sensor rooms to spot early problems in hospitalized cancer patients
This test will try whether special hospital rooms with cameras, microphones, and temperature sensors can help staff spot early delirium, falls, sleep problems, or mood changes in adults hospitalized with cancer.
-
Voices: sharing messages of wisdom and hope during illness
This project will see if recording semi-structured interviews with adult cancer patients (and optional caregivers) affects patients' sense of dignity and caregiver support.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.